Eli Lilly and Company
LLY
$660.49
$21.063.29%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 90.78% | 23.02% | 101.39% | 1,790.42% | 68.27% |
| Total Depreciation and Amortization | 15.47% | 15.53% | 25.05% | 13.58% | 13.13% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -52.92% | 560.47% | -169.25% | 119.13% | 21.49% |
| Change in Net Operating Assets | -61.74% | -92.11% | 29.86% | -101.24% | -66.52% |
| Cash from Operations | 110.54% | 42.85% | 893.14% | 69.53% | 132.03% |
| Capital Expenditure | -38.56% | -53.05% | -39.73% | -39.20% | -65.92% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | 100.00% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -425.95% | -863.30% | 47.55% | -25.77% | -109.39% |
| Cash from Investing | 16.55% | -184.67% | 34.33% | -30.00% | -378.92% |
| Total Debt Issued | -- | 0.13% | -100.00% | 5,018.14% | -- |
| Total Debt Repaid | -69.86% | 64.48% | -- | -306.23% | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -14.89% | -15.15% | -14.75% | -15.18% | -15.19% |
| Other Financing Activities | -280.00% | -76.06% | -43.99% | -595.59% | 48.72% |
| Cash from Financing | -180.03% | 543.21% | -106.36% | -63.06% | 250.52% |
| Foreign Exchange rate Adjustments | 562.25% | 471.55% | -431.40% | 4,181.13% | -747.83% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -62.98% | 51.14% | -122.98% | 146.35% | 189.66% |